HCCK the B max values being 121550±45550 and 84880±5380 sites/cell, respectively. From these data the calculated K D values were 1.1±0.06 (HFLS) and 3.1±1.7 (HCCK) nM. Inhibition curves were performed with antagonists (1 pM-1 mM) or unlabelled BK at the [ 3 H]BK binding (1.5 nM). K i values for BK were 0.93±0.12 (HFLS) and 0.83±0.12 (HCCK) nM. Both antagonists displayed high affinity values: MEN16132 K i values of 1.35±0.05 and 1.75±0.35 nM in HFLS and HCCK, respectively, and icatibant was 3-to 5-fold less potent, K i values being 4.6±1.7 and 8.8±2.9 nM. BK induced IP accumulation both in HFLS (EC 50 0.73±0.08 nM) and HCCK (EC 50 0.64±0.05 nM), and the induced maximal effect was 11±3 (HFLS) and 15±1.5 (HCCK) fold over the basal response. The antagonists potency was evaluated by preincubating cells with MEN16132 or icatibant at different concentrations (0.1 nM-10 mM) for 15 min before the agonist concentration-response curve (0.03 nM-100 mM). Both antagonists displayed a concentration-dependent antagonism, by shifting to the right the BK curve, but MEN16132 displayed a greater potency in respect to icatibant. 1. Leukotriene B4 stabilized cyclooxygenase-2 mRNA and cyclooxygenase-2 protein levels in Il-1b-treated human synovial fibroblasts, leading to the increase of prostaglandin E2 production. 2. Leukotriene B4 stabilized cyclooxygenase-2 mRNA on posttranscriptional level through the cyclooxygenase-2 mRNA 3 -UTR region in Il-1b-treated human synovial fibroblasts. There is no transcriptional regulation in this stabilization effect of leukotriene B4. 3. Leukotriene B4 exerts this stabilization through Raf/MEK1/ERK1/2 signaling pathway in Il-1b-treated human synovial fibroblasts. 4. The AU-containing proximal region of cyclooxygenase-2 mRNA 3 -UTR is more important for this stabilization effect of leukotriene B4 in Il-1b-treated human synovial fibroblasts than more distal AU rich sequences. Conclusions: The pathogenic mechanisms responsible for arthritis remain poorly understood both systemically and in the microenvironment of the diarthrodial joint. Mast cells are detected in the synovial membrane of osteoarthritis patients. We demonstrate the potential cellular and molecular interactions between mast cells and mast-cell derived inflammatory mediators and resident human synovial fibroblasts. We hypothesize that mast-cell derived leukotrienes contribute to synovial inflammation through stabilization of synoviocyte cyclooxygenase-2 expression. Purpose: Inflammation plays an important role in promoting articular cartilage damage in joint diseases such as osteoarthritis (OA). Chondrocytes and synovial fibroblasts (SFs) are involved in joint inflammation by releasing biochemical mediators (NO, prostaglandins) and pro-inflammatory cytokines which lead to the decrease of chondrocyte anabolic activity and the increase of extracellular matrix degradation. Therefore, to prevent cartilage damage, therapies should aim both to enhance chondrocyte anabolic activity and to control inflammation. Electromagnetic fields (EMFs) stimulate anabolic activities in cartilage explants and prevent the catabolic effect of the inflammatory cytokine Il-1. In vivo EMFs retard the development of OA lesions in guinea pigs; in humans they have been successfully used for the treatment of OA. Adenosine is known to reduce inflammation in several models by interacting with four receptors (A 1 , A 2A , A 2B and A 3 ). The role of adenosine for managing joint inflammation has been recently documented and drugs with adenosine A 2A receptor agonist activity have shown chondroprotective effects. The aim of this study was to investiga the potential anti-inflammatory activities of EMFs by the characterization of their effects on adenosine receptors in bovine chondrocytes and SFs. The functional interaction among adenosine A 2A analogs and EMFs in SFs was analyzed by evaluating the production of cAMP, an intracellular mediator, the release of prostaglandin E2 (PGE2) and cyclooxygenase-2 (COX-2) expression. Methods: Chondrocytes and SFs isolated from bovine articular joints were cultured in vitro. The effects of EMFs (1.5 mT, 75 Hz) on adenosine receptors were investigated by saturation and competition binding experiments. Adenylyl cyclase assays were performed to evaluate cAMP levels induced by the A 2A agonist, CGS 21680 (2-[p-(2-carboxyethyl)-phenetylamino]-5 -N-ethyl-carboxamido adenosine) and the A 2 agonist, NECA (5 -N-ethyl-carboxamido adenosine) in the absence and in the presence of EMFs. CGS 21680 and NECA were added to SFs untreated or treated with TNF-alpha (10 ng/ml) in the absence or in the presence of EMFs. PGE2 release was measured by immunoassay and COX-2 expression was evaluated by RT-PCR. Results: EMFs evoke the upregulation of the A 2A and A 3 receptors in both SFs and chondrocytes. The increase in A 2A receptor density (1.9 and 2.4 folds, p < 0.01 respectively in chondrocytes and SFs) was associated to an increase in cAMP levels indicating the functionality of the receptors in EMF-exposed cells. TNF-alpha stimulated PGE2 release in SFs. CGS 21680 and NECA significantly inhibited PGE2 production respectively of 49% and 55%; EMFs inhibited PGE2 release of 63% (vs. TNF-alpha, p < 0.01) and strongly enhanced the inhibition induced by the agonists. Modification of COX-2 expression mirrored changes in PGE2 levels. Conclusions: This study supports anti-inflammatory activity of EMFs mediated by an up-regulation of A 2A receptors and shows a molecular action mechanism by which EMFs act. The in vitro EMF anti-inflammatory activity is consistent with the decrease in inflammatory cytokines expression in the articular cartilage of OA animals. Noteworthy, the biophysical modulation of adenosine pathways has been used in humans as a therapeutic intervention to control the inflammatory microenvironment in in arthroscopic procedures. 
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Purpose:
The production of inflammatory mediators may contribute to osteoarthritis (OA) pathology. High mobility group box chromosomal protein 1 (HMGB1) acts as a pro-inflammatory cytokine in a wide range of cells and binds to the receptor for advanced glycation products (RAGE), a pathway leading to catabolic responses in articular tissues. Of particular interest in the regulation of inflammatory and catabolic processes is the heme oxygenase-1 (HO-1) pathway, which is able to counteract cellular stress in vitro and in vivo. The present study was aimed at identifying a possible regulatory effect of HO-1 on HMGB1 in OA synoviocytes. Methods: Synovial tissue samples were obtained from 15 OA patients undergoing total knee joint replacement. Synoviocytes (fibroblasts and macrophage-like) were obtained by digestion with collagenase IA, cultured in third passage and treated with interleukin-1b (Il-1b, 100 U/ml) for 24 h. HO-1 was induced by treatment with cobalt protoporphyrin IX (CoPP, 10 mM). Matrix metalloproteinase (MMP) activity was determined by fluorometric procedures and HMGB1 release by ELISA. Protein expression was studied by Western blot. Results: Basal expression of HMGB1 protein was reduced by HO-1 induction in OA synoviocytes. In addition, HMGB1 release into the medium was significantly decreased. Stimulation of synoviocytes with Il-1b resulted in an enhancement of HMGB1 cellular content and release. Our results indicate that both processes are down-regulated by HO-1 overexpression. In addition, HO-1 reduced RAGE expression in these cells. The effects of HO-1 induction were prevented when synoviocytes were transfected with a siRNA specific for human HO-1. In cells without HO-1 induction, HO-1 gene silencing resulted in the up-regulation of HMGB1 and RAGE. Regulation of HMGB1 by HO-1 was accompanied by the inhibition of MMP activity in synoviocytes stimulated with Il-1b. Conclusions: Our data provide evidence that HO-1 can regulate HMGB1 in OA synoviocytes. Overall, HO-1 signaling appears to be an appropriate target for the development of novel therapies affecting articular disorders.
EFFECT OF EPIGALLOCATECHIN GALLATE ON THE
INFLAMMATORY RESPONSE OF Il-1-EXPOSED SYNOVIAL FIBROBLASTS P. Sfriso, F. Oliviero, A. Scanu, R. Luisetto, U. Fiocco, L. Punzi.
University of Padova, Padova, ITALY
Purpose: Inflammation is increasingly recognized as contributing to the symptoms and progression of osteoarthritis (OA). Synovitis is a factor that likely contributes to dysregulation of chondrocyte function, favoring an imbalance between the catabolic and anabolic activities of the chondrocyte in remodeling the cartilage. In recent years, significant interest has emerged in the beneficial health effects attributed to the green tea polyphenols. Polyphenols in green tea are potent antioxidants, with the majority of the beneficial effects elicited by epigallocatechin-3-gallate (EGCG), one of the main constituent of green tea. Among several inflammatory mediators, interleukin-1beta (Il-1) plays a pivotal role in the pathophysiology of OA. We therefore assessed the effect of EGCG on the production of interleukin-8 (Il-8) and interleukin-1 receptor antagonist (Il-1ra) in primary cultured synovial fibroblasts stimulated with Il-1. Methods: Human synovial fibroblasts were stimulated for 24 hours with Il-1 (10 ng/ml) in the presence or absence of EGCG (0.1−5 mM). The levels of Il-8 and Il-1ra were measured in cell supernatants by enzyme-linked immunoassay methods. The lack of cell cytotoxicity of EGCG was ensured using the colorimetric MTT assay. Results: Treatment of synovial fibroblasts with EGCG resulted in a marked inhibition of Il-1-induced Il-8 production. EGCG also increased in a dose-dependent manner the release of Il-1ra by stimulated fibroblasts.
Conclusions: The present study shows that EGCG, at dose comparable with plasma concentration achieved by the consumption of two cups of tea, suppressed the inflammatory response of Il-1-exposed synovial fibroblasts. The suppressive effect of EGCG may be due to the interference with inflammatory signal transduction pathway or may be related to the inhibition of the release and the accumulation of reactive oxygen species. Our findings suggest that EGCG may be of potential therapeutic value in the treatment of OA.
EFFECT OF EPIGALLOCATECHIN GALLATE ON CALCIUM CRYSTAL-INDUCED CHEMOTACTIC FACTORS
F. Oliviero, P. Sfriso, A. Scanu, M. Miorin, U. Fiocco, C. Sales, P. Spinella, L. Punzi. University of Padova, Padova, ITALY Purpose: Although osteoarthritis (OA) is defined as a cartilage disease, synovitis involving mononuclear cell infiltration and overexpression of proinflammatory mediators is common in early and late OA. Calcium crystals deposition is a factor that likely contributes to synovial membrane inflammation. Polyphenols in green tea are potent antioxidants, with the majority of the beneficial effects elicited by epigallocatechin-3-gallate (EGCG), one of the main constituent of green tea. The aim of our study was to evaluate if EGCG may influence some inflammatory aspects of OA. To this aim we studied the effect of EGCG on chemotactic factors released by human fibroblasts stimulated with calcium crystals, regular features of the most severe forms of OA. Methods: Human synovial fibroblasts were stimulated with pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP) crystals (0.01−0.1 mg/ml) in the presence or absence of EGCG (0.1−5 mM). Il-1beta (10 ng/ml) was used as a positive control. CPPD and BCP crystals were synthesized by the methods of Cheng and McCarthy respectively. The levels of MCP-1 were measured in cell supernatants by enzyme-linked immunoassay methods. The chemotactic effect of culture supernatants was evaluated on chemotaxis chamber by the migration of fresh-isolated mononuclear blood cells. The lack of cell cytotoxicity of both EGCG and calcium crystals was ensured using the colorimetric MTT assay. Results: EGCG inhibited MCP-1 release by stimulated fibroblasts in a dose-dependent manner. Supernatants of crystals-stimulated cells loose their ability to induce mononuclear cell migration when EGCG was added in the medium. EGCG inhibited both MCP-1 release and supernatants chemotactic activity of Il-1beta stimulated culture in a dose-dependent manner.
Conclusions: The present study shows that EGCG, at dose comparable with plasma concentration achieved by the consumption of two cups of tea, modify the inflammatory response of calcium crystal-exposed synovial fibroblasts. EGCG may interfere with inflammatory signal transduction pathway and may also inhibits the cellular generation, the release and the accumulation of reactive oxygen species. Our results suggest that EGCG might represents a good candidate for the prevention and treatment of OA. Purpose: Prostaglandin E2 (PGE2) is an eicosanoid with pleiotropic properties that binds G-protein coupled receptors, effecting changes in cell signalling through activation of protein kinases and phosphatases. We examined PGE2-dependent control of the dual specificity phosphatase-1 (DUSP-1) in arthritis-affected human synovial fibroblasts (HSF) in culture and in the dorsal air-pouch mouse model of synovial inflammation in vivo.
MODULATION OF THE INFLAMMATORY AND CATABOLIC

RESPONSE BY PROSTAGLANDIN E2 (PGE2) IS PARTIALLY DEPENDENT ON THE INDUCTION OF DUAL
Methods:
• Cultured human synovial fibroblasts (HSF) were obtained by sequential enzymic digestion from osteoarthritis-affected synovial membranes.
• Western and Northern blot analyses were used to measure protein, phosphorylated protein and mRNA expression, respectively. • Transient transfection assays were employed to express activated signaling molecules, shRNA constructs, and to analyze reporter luciferase activity.
• Wild type and DUSP-1 null mice were used in the dorsal air pouch studies. Analytes were measured by ELISA and RT-PCR. Cell infiltration measurements were assessed by flow cytometry.
• Statistical analyses included Student's T-test and ANOVA Results: PGE2 induced a robust (7 fold) and rapid (10 min) increase in DUSP-1 mRNA in cultured HSF, reaching a zenith at 30−60 min followed by decay to control levels. A late phase of DUSP-1 mRNA expression was observed after 4 h and continued for another 20 h. In transient transfection assays using a DUSP-1 promoter-luciferase reporter construct or a luciferase reporter construct harbouring the DUSP-1 mRNA 3 -UTR region fused 3 prime, PGE2 induced a modest (1.38) increase in promoter (transcriptional) activity while also stabilizing luciferase-DUSP-1 3 UTR mRNA chimeric transcripts (2.6 fold; post-transcriptional regulation). With respect to DUSP-1 protein, PGE2 induced a similar bi-phasic pattern as observed with DUSP-1 mRNA, appearing within 20−30 min, a plateau at 60 min, with protein levels declining to near control levels. A second phase of protein expression was observed from 4 h and DUSP-1 protein was still detectable after 24 h. In terms of measuring DUSP-1 phosphatase activity, PGE2 abrogated rhIl-1b induced phosphorylation of T183/Y185 of SAPK/JNK, a response abolished by knock down of DUSP-1 through targeting by over expression with either a shRNA expression construct or the DUSP-1 inhibitor sanquinarine sulfate. Using specific PGE2 receptor (EP) agonists and antagonists, we observed that the PGE2-dependent
